Clinical trial · Interventional
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer
NCT00128596CI-TRIAL-00027251completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic liver cancer that cannot be removed by surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| arsenic trioxide | Drug | Arsenic Trioxide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Efficacy
- measure
- Safety and tolerability
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed hepatocellular carcinoma * Unresectable metastatic disease * Ascites allowed provided it is minimal PATIENT CHARACTERISTICS: Age * Over 18 Performance status * 0-2 Life expectancy * Not specified Hematopoietic * WBC \> 2,500/mm\^3 * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count \> 75,000/mm\^3 Hepatic * Bilirubin \< 2.5 mg/dL * AST \< 2.5 times upper limit of normal Renal * Not specified Cardiovascular * QTc interval ≤ 460 msec AND potassium and magnesium normal Other * Not pregnant or nursing * Negative pregnancy test * Fertile female patients must use effective double-method contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment (during and for ≥ 4 weeks after completion of study treatment for male patients) * No blood, ova, or sperm donation during study treatment * Potassium \> 4.0 mEq/dL * Magnesium \> 1.8 mg/dL PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent biologic therapy Chemotherapy * More than 4 weeks since prior and no other concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * More than 4 weeks since prior and no concurrent radiotherapy Surgery * Not specified Other * No other concurrent investigational agents
References
Publications (0)
Data not yet available
No reference posted for this study.